Evidence map›Paper›PMID 33737643›Full record

ArticleScientific reports2021

A dose-escalating toxicology study of the candidate biologic ELP-VEGF.

Jamarius P Waller, Stephen P Burke, Jason Engel, Alejandro R Chade, Gene L Bidwell

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Angiogenic Doping: Plausible Yet Difficult to Detect.Sports medicine (Auckland, N.Z.) · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Novel Drug Delivery Technologies and Targets for Renal Disease.Hypertension (Dallas, Tex. : 1979) · 2022
    Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jamarius P WallerDepartment of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA.
Stephen P BurkeDepartment of Neurology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA.
Jason EngelDepartment of Physiology and Biophysics, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA.
Alejandro R ChadeDepartment of Physiology and Biophysics, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA.
Gene L BidwellDepartment of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA. gbidwell@umc.edu.
State Street (United States) · USJackson Memorial Hospital · USUniversity of Mississippi Medical Center · US

Funding

STRUCTURAL VASCULAR ADAPTATION OF THE MICROCIRCULATIONP01HL051971 · NHLBI · UNIVERSITY OF MISSISSIPPI MEDICAL CENTER · PI HALL, JOHN E · 1993 to 2018
$39.4M
The role of leptin in autoimmune-associated hypertensionP20GM104357 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI TAYLOR, ERIN BASSFORD · 2013 to 2022
$23.4M
A Novel Protein Delivery System for Therapy of PreeclampsiaR01HL121527 · NHLBI · UNIVERSITY OF MISSISSIPPI MED CTR · PI BIDWELL, GENE LEFLORE · 2014 to 2023
$4.1M
Microcirculation in Renovascular HypertensionR01HL095638 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI CHADE, ALEJANDRO ROBERTO · 2010 to 2021
$3.9M
A Preclinical Trial of Therapeutic Angiogenesis Plus Angioplasty and Stenting for Renal Vascular DiseaseR41DK109737 · NIDDK · LEFLORE TECHNOLOGIES, LLC · PI BIDWELL, GENE LEFLORE · 2017 to 2017
$216k
The use of a biopolymer-fused form of VEGF-B for the treatment of Preeclampsia.F31HL151180 · NHLBI · UNIVERSITY OF MISSISSIPPI MED CTR · PI WALLER, JAMARIUS · 2020 to 2022
$86k
NHLBI NIH HHS F31 HL151180NHLBI NIH HHS P01 HL051971NHLBI NIH HHS R01 HL095638NHLBI NIH HHS R01 HL121527NIDDK NIH HHS R41 DK109737NIGMS NIH HHS P20 GM104357
6 · The paper itself

Abstract

Vascular Endothelial Growth Factor (VEGF), a key mediator of angiogenesis and vascular repair, is reduced in chronic ischemic renal diseases, leading to microvascular rarefaction and deterioration of renal function. We developed a chimeric fusion of human VEGF-A

Indexed as

AnimalsBiological ProductsBlood PressureBody WeightBreast NeoplasmsCapillary PermeabilityDisease Models, AnimalElastinFemaleGene ExpressionGlomerular Filtration RateHeterograftsHumansHypotensionMiceMolecular MimicryBiological ProductsElastinRecombinant Fusion ProteinsVascular Endothelial Growth Factor A

Identifiers

PMID33737643
PMCPMC7973730
OpenAlexW3137403108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.